Schnitzler Syndrome — Structured Data
AI-optimized single page. All data for Schnitzler Syndrome in dense, structured format. Last updated: 2026-04-15.
View interactive disease hub · View all sources
Key Statistics
- Total reported cases
- 748
- Mean onset age
- 53 years
- Onset range
- 13–71 years
- Sex ratio (M:F)
- 1.76:1
- Diagnostic delay
- ~5 years
- Discovered
- 1972 (Liliane Schnitzler)
- Prevalence
- <1/1,000,000
- Classification
- autoinflammatory, hematologic
- Pathophysiology
- partially understood
- Treatment status
- effective options available
- Genetic basis
- under investigation
- Aliases
- Schnitzler's Syndrome, SchS
Symptoms (13)
| Symptom | Frequency | Severity | Category | Description |
|---|---|---|---|---|
| Chronic urticarial rash | 100% | cardinal | dermatologic | Non-pruritic or mildly pruritic wheals, often worse in evening. Individual lesions last <24 hours. Neutrophilic dermal infiltrate on biopsy. |
| Monoclonal IgM gammopathy | 100% | cardinal | laboratory | Obligate diagnostic criterion. IgM-kappa in ~94% of cases. M-spike often low (median 0.6 g/dL). SPEP alone may miss it in 51% — immunofixation required. |
| Recurrent fever | 85% | major | systemic | Intermittent fever >38°C, often in evening. Resolves within hours of anakinra. |
| Bone pain | 70% | major | musculoskeletal | Predominantly distal femora and proximal tibiae ('hot knees'). Osteosclerotic lesions on imaging in 64%. |
| Arthralgia | 75% | major | musculoskeletal | Joint pain without destructive arthropathy. Large joints most commonly affected. |
| Fatigue | 80% | major | systemic | Often severe and debilitating. Correlates with inflammatory marker levels. |
| Elevated CRP | 95% | major | laboratory | Consistently elevated C-reactive protein reflecting systemic inflammation. Normalizes rapidly with IL-1 blockade. |
| Elevated ESR | 90% | major | laboratory | Erythrocyte sedimentation rate >20 mm/h. Minor criterion in Lipsker criteria. |
| Leukocytosis | 65% | minor | laboratory | White blood cell count >10,000/μL with neutrophilia. |
| Weight loss | 40% | minor | systemic | Unintentional weight loss due to chronic inflammation. |
| Lymphadenopathy | 30% | minor | systemic | Palpable lymph nodes, usually mild. |
| Hepatomegaly/splenomegaly | 25% | minor | systemic | Organ enlargement reflecting systemic inflammation. |
| Myalgia | 50% | minor | musculoskeletal | Muscle pain, often accompanying fever episodes. |
Molecular Pathway (13 molecules)
| Molecule | Role | Expression change | Evidence level | Targeted by | Explanation |
|---|---|---|---|---|---|
| IL-1β | Central pathogenic driver | Elevated | established | Anakinra, Canakinumab | IL-1β is the key cytokine driving Schnitzler inflammation. Proven by the dramatic, rapid response to anakinra — symptoms resolve within hours, confirming IL-1β as the effector molecule. |
| NLRP3 | Inflammasome sensor | Dysregulated | strong | — | NLRP3 assembles the inflammasome that activates caspase-1, which cleaves pro-IL-1β into active form. Unlike CAPS (gain-of-function mutation), no consistent NLRP3 mutation found. |
| MYD88 | TLR signalling adaptor | L265P in ~30% | moderate | Ibrutinib (indirect) | MYD88 L265P is found in ~30% of Schnitzler patients and >90% of Waldenström's cases. Drives NF-κB activation. |
| NF-κB | Master transcription factor | Persistently active | strong | Bortezomib (indirect) | Convergence point — both NLRP3/IL-1β and MYD88 pathways activate NF-κB, which drives inflammatory cytokine production. |
| Caspase-1 | IL-1β converting enzyme | Constitutively active | moderate | — | Sits between NLRP3 and IL-1β. When NLRP3 assembles, caspase-1 cleaves pro-IL-1β into mature form. |
| IL-6 | B-cell growth factor | Elevated | strong | Tocilizumab | IL-6 promotes B-cell differentiation and IgM secretion. Consistently elevated, but IL-6 blockade (tocilizumab) gives only temporary benefit. |
| IL-18 | NK cell activator | Elevated | moderate | — | Another inflammasome product (cleaved by caspase-1 alongside IL-1β). Elevated levels may drive IgM-producing B-cell expansion. |
| TNFα | Pro-inflammatory cytokine | Elevated | moderate | — | Elevated but TNF-blockers are INEFFECTIVE in Schnitzler syndrome. This tells us TNFα is a bystander, not a driver. |
| BTK | B-cell receptor kinase | Active | moderate | Ibrutinib | Downstream of MYD88 in B-cell signalling. Also regulates NLRP3 inflammasome. Ibrutinib (BTK inhibitor) reduces both symptoms AND IgM levels. |
| Gasdermin D | Membrane pore former | Active | emerging | — | Mediates IL-1β release and pyroptosis. Part of the downstream inflammasome execution pathway. |
| MRP8/14 (S100A8/A9) | Neutrophil inflammatory markers | Elevated | strong | — | Correlate with disease activity. Normalize with IL-1 blockade. Useful biomarkers for monitoring treatment response. |
| CCL2 | Monocyte chemoattractant | Elevated | moderate | — | Elevated in patient serum. Produced by PBMCs and dermal fibroblasts upon IL-1β stimulation. Recruits mononuclear cells to skin and bone. |
| IgM (monoclonal) | Diagnostic paraprotein | Present (obligate) | established | Ibrutinib (reduces), Rituximab (reduces but ineffective on symptoms) | Obligate diagnostic criterion. Kappa light chain predominance (15:1). Relationship to inflammation is the central unsolved mystery. |
Genetic Findings (6)
| Gene | Variant | Type | Frequency in disease | Significance | Also found in |
|---|---|---|---|---|---|
| MYD88 | L265P (somatic) | somatic | ~30% of tested patients | The most significant genetic finding. Same mutation found in >90% of Waldenström's macroglobulinemia. Drives persistent NF-κB activation. | Waldenström's macroglobulinemia (>90%) |
| NLRP3 | Somatic mosaicism (various) | somatic | Rare (2 confirmed cases) | Found in patients with the most severe phenotypes. Demonstrates that NLRP3 can be directly causative in some cases. | CAPS (Nearly all cases (germline)) |
| NLRP3 | V198M | germline | 1 family studied | Found in 1 patient but 4 asymptomatic carriers across 3 generations — insufficient alone to cause disease. | CAPS (mild forms) (Occasional) |
| MEFV | c.2084A>G and p.(Glu148Gln) | germline | Emerging (2024-2025 reports) | MEFV encodes pyrin, an inflammasome inhibitor. Variants could lower the threshold for inflammasome activation. | Familial Mediterranean Fever (Causative (homozygous/compound het)) |
| F2 | 3′UTR c.*97G>A | germline | 1 case (2025) | Novel finding in the 748th reported case. F2 encodes prothrombin — role in inflammasome regulation unclear. | — |
| DPP10 | Autoantigen target | not_found | Identified as IgM target | DPP10 identified as a reactive autoantigen for the monoclonal IgM in some patients. | — |
Treatment Evidence Matrix (8 treatments)
| Drug | Mechanism | Route | Response rate | Onset | IgM effect | Line | Explanation |
|---|---|---|---|---|---|---|---|
| Anakinra | IL-1 receptor antagonist | SC 100mg daily | ~94% | Hours–days | No effect | 1st | Blocks IL-1 receptor. Cornerstone treatment — fever and rash resolve within hours, CRP normalises within days. ~94% response across all published cases. |
| Canakinumab | Anti–IL-1β monoclonal antibody | SC 150mg every 4–8 weeks | High (RCT confirmed) | Days–weeks | No effect | 2nd | Directly neutralises IL-1β with long half-life. The only RCT in Schnitzler (Krause et al. 2015) demonstrated sustained efficacy. De Koning et al. 2013 showed sustained remission in a 9-month trial. |
| Ibrutinib | BTK inhibitor | Oral 420mg daily | Complete in case reports | 2 weeks – 3 months | Reduces IgM | Alternative | The only drug shown to reduce both inflammatory symptoms AND IgM levels. Three case reports (2018–2022) demonstrate efficacy, including one MYD88 L265P-positive patient where IgMκ monoclonal protein declined — unique among all treatments. |
| Rilonacept | IL-1 decoy receptor (IL-1 Trap) | SC 160mg load, then 80mg weekly | Limited data | Weeks | No effect | Alternative | Dimeric fusion protein acting as IL-1 'trap', neutralising both IL-1α and IL-1β. Krause et al. 2012 demonstrated efficacy and safety in an open-label study in Schnitzler syndrome. Less widely used than anakinra/canakinumab. |
| Tocilizumab | Anti–IL-6 receptor | SC or IV | Initial response, loss of efficacy | Weeks | Unknown | Alternative | IL-6 is elevated in Schnitzler syndrome, but a 9-patient open-label study (2024) showed initial clinical/biological response with subsequent loss of efficacy over time. May be considered for rare IL-1-refractory cases. |
| Rituximab | Anti-CD20 (B-cell depletion) | IV infusion | Ineffective on inflammation | — | Reduces IgM | Not recommended | Depletes B cells and can reduce IgM, but doesn't control inflammatory symptoms. |
| Corticosteroids | Broad anti-inflammatory | Oral | Temporary, partial | Days | No effect | Not recommended | Temporary symptom relief, but disease invariably recurs on tapering. |
| Bortezomib | Proteasome inhibitor (NF-κB pathway) | SC or IV | Single case report | Unknown | Unknown | Investigational | Novel approach targeting the NF-κB pathway. Bai et al. 2025 reported use in a patient without detectable serum IL-1β who was negative for monogenic autoinflammatory variants and MYD88 L265P. Very preliminary. |
Diagnostic Criteria
Lipsker Criteria (2001)
Sensitivity: 100% · Specificity: 97%
Major criteria (all required)
- Chronic urticarial rash
- Monoclonal IgM component
Minor criteria (2+ required)
- Recurrent fever (>38°C)
- Arthralgia or arthritis
- Bone pain
- Lymphadenopathy
- Hepatomegaly and/or splenomegaly
- Elevated ESR (>20 mm/h)
- Leukocytosis (>10,000/μL)
- Abnormal bone imaging findings
Both major criteria required plus ≥2 minor criteria. Validated by Gusdorf et al. 2017.
Strasbourg Criteria (2013)
Sensitivity: 81% (definite), 93% (probable) · Specificity: 100% (definite), 97% (probable)
Major criteria (all required)
- Chronic urticarial rash
- Monoclonal IgM OR IgG gammopathy
Minor criteria (2+ required)
- Recurrent fever (>38°C)
- Objective findings of abnormal bone remodeling with or without bone pain
- Neutrophilic dermal infiltrate on skin biopsy
- Elevated CRP and/or leukocytosis
Both obligate criteria required. For IgG variant, ≥3 minor criteria required instead of ≥2.
Differential Diagnoses (6)
| Condition | Key distinction | Shared features |
|---|---|---|
| Adult-Onset Still's Disease | Rash is evanescent salmon-colored (not urticarial). Markedly elevated ferritin. No monoclonal gammopathy. | Quotidian fever, Arthralgia, Leukocytosis, Elevated CRP |
| Cryopyrin-Associated Periodic Syndromes (CAPS) | Genetic: NLRP3 germline mutations. Typically childhood onset. Family history. | Urticarial rash, Fever, IL-1β driven, Responds to IL-1 blockade |
| Urticarial vasculitis | Skin biopsy shows vasculitis. Individual lesions last >24 hours. Often painful. | Chronic urticarial rash, Systemic symptoms possible |
| Chronic spontaneous urticaria | Responds to antihistamines (Schnitzler does not). No monoclonal gammopathy. | Chronic urticarial rash |
| Waldenström's macroglobulinemia | Higher IgM levels. Bone marrow lymphoplasmacytic infiltration. No urticarial rash. | Monoclonal IgM, MYD88 L265P, Can develop from Schnitzler |
| Systemic mastocytosis | Mast cell infiltration on biopsy. Elevated serum tryptase. | Skin lesions, Systemic symptoms, Bone involvement possible |
Hypotheses (7)
| Hypothesis | Domain | Status | Evidence score | Studies | Evidence for | Evidence against |
|---|---|---|---|---|---|---|
| Shared MYD88/NF-κB mechanism drives both autoinflammation and B-cell clonality | pathogenesis | leading | 55/100 | 48 |
|
|
| Independent parallel processes: inflammasome dysregulation and MGUS are separate consequences of an upstream event | pathogenesis | competing | 35/100 | 30 |
|
|
| IL-1 blockade may prevent lymphoproliferative transformation to Waldenström's | treatment | competing | 30/100 | 12 |
|
|
| Schnitzler syndrome is a spectrum, not a single disease | pathogenesis | emerging | 30/100 | 15 |
|
|
| Monoclonal IgM directly triggers inflammasome activation (autoantibody model) | pathogenesis | weakening | 25/100 | 22 |
|
|
| NLRP3 somatic mosaicism is the primary driver in a subset of patients | genetics | emerging | 20/100 | 8 |
|
|
| Pyrin-inflammasome dysfunction (MEFV variants) contributes to pathogenesis | genetics | emerging | 15/100 | 4 |
|
|
Open Questions (6)
- What is the relationship between the monoclonal gammopathy and the autoinflammation?
Three competing hypotheses exist. MYD88 L265P is the strongest candidate for a shared mechanism but is absent in ~70% of patients. - What triggers the initial inflammasome dysregulation?
No consistent genetic mutation identified. Environmental triggers? Stochastic cellular events? Epigenetic dysregulation? - Does IL-1 blockade prevent lymphoproliferative transformation?
Suggestive data from the French cohort but IL-1 therapy does not alter monoclonal component levels. Needs long-term prospective studies. - Can ibrutinib address both the inflammatory and gammopathy components simultaneously?
Only agent shown to reduce monoclonal protein AND control symptoms. Very limited data. Needs prospective trials. - Is Schnitzler syndrome truly a single disease or a spectrum?
Growing recognition of IgG variants, Schnitzler-like syndromes without gammopathy, and molecular subtypes. - What is the role of newly identified genes (MEFV, F2)?
MEFV variants found in some patients (2024-2025). MEFV encodes pyrin (inflammasome inhibitor). Significance uncertain.
Complications (3)
| Complication | Risk | Timeframe | Description | Monitoring |
|---|---|---|---|---|
| Lymphoproliferative transformation | 15-20% at 10 years | Median 8 years | Most commonly Waldenström's macroglobulinemia (WM) or lymphoplasmacytic lymphoma (LPL). | Annual SPEP/immunofixation; complete blood count every 6 months |
| AA amyloidosis | ~3-5% | Years of uncontrolled inflammation | Secondary amyloidosis due to chronic inflammation. Can cause renal failure. | Annual serum amyloid A level; renal function monitoring |
| Osteoporosis / pathologic fractures | Variable | — | Chronic bone inflammation can lead to structural weakening. | DEXA scan; bone scintigraphy if symptomatic |
Sources (79)
| Ref | Authors | Title | Journal | Year | Category | Type | Grade | Link |
|---|---|---|---|---|---|---|---|---|
| D7 | Hiroyasu S, Fukumoto K, Nakashima Y, Akaji T, Itoh Y, Tsuruta D | IgA λ-type Schnitzler syndrome with edema and numbness | J Dermatol | 2026 | clinical | case report | C | DOI |
| G11 | Santaniello U, Borriello S, Cavaliere G, Brizio MG, Ribero S, Quaglino P | Clinical effectiveness and safety of anakinra in an octogenarian patient with Schnitzler Syndrome | Ital J Dermatol Venerol | 2026 | treatment | case report | D | DOI |
| M3 | Mir TH, Patell R, Freed JA | Monoclonal gammopathies of cutaneous significance: A nomenclature and pathophysiology-based classification. | J Am Acad Dermatol | 2026 | diagnostics | letter | D | DOI |
| C7 | Műzes G, Sipos F | Background and Clinical Features of a Unique and Mysterious Autoinflammatory Disease, Schnitzler Syndrome | Int J Mol Sci | 2025 | genetics | case report | C | DOI |
| E3 | Aminianfar M, et al. | First reported Schnitzler syndrome cases in Iran | J Cutan Immunol Allergy | 2025 | epidemiology | case report | D | — |
| I8 | Bai H, Zhou D, Liu J, He J, Min Z, Fan W, Chen B, Xu Y | Bortezomib in Schnitzler syndrome without detectable IL-1β | Front Immunol | 2025 | treatment | case report | D | DOI |
| J8 | Zhu C, Martinez-Jaramillo E, Ben Shoshan M, Netchiporouk E, Chergui M, Fein M | Schnitzler syndrome without monoclonal gammopathy: a systematic review and case presentation | Clin Exp Dermatol | 2025 | reviews | systematic review | B | DOI |
| K2 | Calabrese L, Cartocci A, et al. | IL-1 targeting agents in Schnitzler syndrome: a multicentre, real-world study from the international AIDA Network | Clin Exp Rheumatol | 2025 | treatment | cohort | B | DOI |
| K3 | Kambe N, Inoue M, et al. | Neutrophils predominate as IL1B-expressing cells in Schnitzler syndrome: Insights from the SCan study | Allergol Int | 2025 | pathogenesis | cohort | B | DOI |
| K5 | Caggiano V, Sbalchiero G, et al. | Clinical and laboratory markers to distinguish VEXAS from Schnitzler syndrome: data from the AIDA network registries | Front Med | 2025 | diagnostics | cohort | B | DOI |
| K6 | Daskalopoulou A, Assrawi E, et al. | Low-level NLRP3 mosaicism in chronic urticarial lesions: extending the phenotypic spectrum of NLRP3-related disorders | Br J Dermatol | 2025 | genetics | case series | C | DOI |
| K7 | De Santos Belinchón S, Ausín García C, et al. | Canakinumab as effective therapy in anakinra-refractory Schnitzler syndrome: a case-based review | Intern Med J | 2025 | treatment | case report | C | DOI |
| K8 | Ahmad S, Dunne G, et al. | Paraprotein-Negative IL-1-Mediated Inflammatory Dermatosis: An Update on Schnitzler-Like Syndrome | JID Innovations | 2025 | pathogenesis | narrative review | B | DOI |
| K9 | Irino K, Kochi Y, et al. | A case of Schnitzler syndrome complicated by rheumatoid arthritis treated with methotrexate | Mod Rheumatol Case Rep | 2025 | treatment | case report | C | DOI |
| L5 | Mooney N, Grewal A, Pei S, Bogner P, Kuraitis D | Tinea labialis in a patient with Schnitzler syndrome on interleukin-1 receptor antagonist. | JAAD Case Rep | 2025 | treatment | case report | C | DOI |
| L6 | Velusamy B, Pincelli T, Sokumbi O | Letter to the editor - "Re: Tinea labialis in a patient with Schnitzler syndrome on interleukin-1 receptor antagonist". | JAAD Case Rep | 2025 | treatment | letter | D | DOI |
| L7 | Cai X, Zheng Y, Yang C, Xu J, Fang H, Qiao J | Neutrophilic Urticarial Dermatosis: A Window into Systemic Inflammation and Autoimmune Disorders. | Clin Rev Allergy Immunol | 2025 | pathogenesis | systematic review | C | DOI |
| L8 | Gialama D, Bonnekoh H, Rothermel ND, Oldenburg R, Khan DA, Hoffman HM, Lang D, Kolkhir P | Differential Diagnosis of Chronic Spontaneous Urticaria. | J Allergy Clin Immunol Pract | 2025 | diagnostics | case report | C | DOI |
| L9 | Caterson HC, Papadopoulou C, Peet C, Lachmann HJ | Systemic autoinflammatory disease diagnoses in a single year from a UK national referral centre. | Rheumatology (Oxford) | 2025 | epidemiology | cohort study | B | DOI |
| M1 | Bishnoi A, Sharma A, Baskaran N, Mehta H, Chatterjee D, Vinay K | Acquired autoinflammatory disorders: a dermatologist's perspective. | Clin Exp Dermatol | 2025 | clinical | review | C | DOI |
| M2 | Mertz P, Chauffier J, Delplanque M | [What is an undifferentiated systemic autoinflammatory disease in adults? Current state of knowledge and practical approach]. | Rev Med Interne | 2025 | diagnostics | review | C | DOI |
| J5 | Braud A, Lipsker D | Most recent comprehensive review | Biomolecules | 2024 | reviews | narrative review | B | DOI |
| J6 | Kanabaj K, et al. | Modern look at Schnitzler syndrome | Acta Dermatovenerol Croat | 2024 | reviews | narrative review | B | PubMed |
| B8 | Li S, et al. | Neutrophil extracellular traps and neutrophilic dermatosis: updated review | Cell Death Discov | 2024 | pathophysiology | narrative review | C | DOI |
| C8 | Lopez-Gonzalez M, et al. | Schnitzler syndrome IgG-kappa variant with MEFV p.(Glu148Gln) | Actas Dermosifiliogr | 2024 | genetics | case report | C | — |
| D2 | Nakaizumi H, et al. | Neutrophilic epitheliotropism in Japanese Schnitzler syndrome cases | J Dermatol | 2024 | diagnostics | case series | C | — |
| I2 | Néel A, et al. | Tocilizumab open-label study: initial response with loss of efficacy | Medicine | 2024 | treatment | cohort | C | — |
| K1 | Singh G, et al. | IgG kappa variant of Schnitzler syndrome | Cureus | 2024 | case reports | case report | D | DOI |
| H3 | Kolivras A, et al. | Canakinumab for anakinra-intolerant Schnitzler syndrome | J Dermatol Treat | 2023 | treatment | case report | C | — |
| I5 | Huang Y, et al. | Ibrutinib for MYD88 L265P-positive Schnitzler | Front Immunol | 2022 | treatment | case report | C | DOI |
| J4 | Qiao J, Yao Q | Schnitzler and Schnitzler-like syndromes review | Clin Rheumatol | 2022 | reviews | narrative review | B | PubMed |
| D6 | Terpos E, et al. | Schnitzler-like syndrome without gammopathy: imaging and canakinumab response | Rheumatology | 2021 | diagnostics | case report | C | — |
| F3 | Adam Z, et al. | Schnitzler syndrome transformation to Waldenström's macroglobulinemia | Vnitr Lek | 2021 | case reports | case series | C | — |
| I4 | Claves F, et al. | Dramatic ibrutinib efficacy in Schnitzler syndrome with indolent lymphoma | J Clin Immunol | 2021 | treatment | case report | C | DOI |
| — | Claves FP, et al. | Ibrutinib in Schnitzler syndrome: a case report | — | 2021 | treatment | case report | C | PubMed |
| B4 | Bonnekoh H, et al. | NETosis in Schnitzler syndrome | Front Immunol | 2019 | pathophysiology | cohort | C | DOI |
| B7 | Van Leersum FS, et al. | Shared MYD88/NF-κB mechanism hypothesis | Orphanet J Rare Dis | 2019 | pathophysiology | expert opinion | C | DOI |
| B3 | Regnault V, et al. | PBMC studies: spontaneous IL-1β release | Scand J Rheumatol | 2019 | pathophysiology | cohort | C | — |
| C4 | Pathak S, et al. | MYD88 L265P in 30% of Schnitzler patients | Arthritis Rheumatol | 2019 | genetics | cohort | B | DOI |
| B6 | Migliorini P, et al. | IL-1 family cytokine profiling in Schnitzler syndrome | Scand J Rheumatol | 2019 | pathophysiology | cohort | C | — |
| C3 | Bashir M, et al. | First reported Schnitzler case with MYD88 L265P mutation | JAAD Case Rep | 2019 | genetics | case report | C | DOI |
| C2 | Rowczenio DM, et al. | 32-gene sequencing study | Blood | 2018 | genetics | cohort | B | DOI |
| I9 | NHS England | Anakinra as first-line treatment policy | NHS England | 2018 | treatment | expert opinion | B | — |
| C6 | Pathak S, et al. | B-cell clonality and DPP10 as IgM autoantigen in Schnitzler syndrome | Immunology | 2018 | genetics | cohort | C | — |
| I3 | Jani P, et al. | Ibrutinib for Schnitzler syndrome with concurrent hematologic malignancy | J Oncol Pract | 2018 | treatment | case report | C | DOI |
| — | Jani P, et al. | Ibrutinib for the management of Schnitzler syndrome: a case report | J Med Case Rep | 2018 | treatment | case report | C | PubMed |
| A6 | Gusdorf L, et al. | Validation of diagnostic criteria | Allergy | 2017 | diagnostics | cohort | B | DOI |
| J3 | Lipsker D | Diagnostic criteria, IL-1 centrality, lymphoproliferative risk on therapy | Curr Rheumatol Rep | 2017 | reviews | narrative review | B | DOI |
| A7 | Gameiro A, et al. | Clinical characterization and long-term follow-up of Schnitzler syndrome | Clin Exp Dermatol | 2016 | diagnostics | cohort | C | DOI |
| B2 | de Koning HD, et al. | IL-1β centrality via canakinumab trial | Arthritis Res Ther | 2015 | pathophysiology | cohort | B | DOI |
| C1 | de Koning HD, et al. | NLRP3 somatic mosaicism in variant Schnitzler | J Allergy Clin Immunol | 2015 | genetics | case series | C | DOI |
| G8 | Vanderschueren S, et al. | Dramatic anakinra response after 10-year refractory disease | J Am Acad Dermatol | 2015 | treatment | case report | C | — |
| H2 | Krause K, et al. | Randomized placebo-controlled trial of canakinumab in Schnitzler syndrome | Pediatr Rheumatol | 2015 | treatment | RCT | A | — |
| A5 | de Koning HD | Comprehensive review (281 cases) | Clin Transl Allergy | 2014 | reviews | narrative review | B | DOI |
| D3 | Niederhauser BD, et al. | Bone imaging findings (22 patients) | Skeletal Radiol | 2014 | diagnostics | cohort | B | DOI |
| G5 | Néel A, et al. | Multicenter anakinra study (29 patients, France) | Autoimmun Rev | 2014 | treatment | cohort | B | DOI |
| G6 | Szturz P, et al. | Czech multicenter anakinra study (6 patients) | Ann Rheum Dis | 2014 | treatment | cohort | B | DOI |
| A4 | Simon A, et al. | Strasbourg criteria for Schnitzler syndrome | Allergy | 2013 | diagnostics | expert opinion | B | DOI |
| E1 | Jain T, et al. | Under-diagnosis at Mayo Clinic | Am J Med | 2013 | epidemiology | cohort | B | — |
| H1 | de Koning HD, et al. | Canakinumab efficacy (9-month trial) | Ann Rheum Dis | 2013 | treatment | cohort | B | DOI |
| B5 | Krause K, et al. | CCL2 elevation in Schnitzler syndrome: mononuclear cell recruitment | J Allergy Clin Immunol | 2013 | pathophysiology | cohort | C | — |
| D1 | Sokumbi O, et al. | Clinico-histopathologic review of Schnitzler syndrome at Mayo Clinic | J Am Acad Dermatol | 2012 | diagnostics | cohort | B | DOI |
| I1 | Krause K, et al. | Rilonacept (IL-1 decoy receptor) efficacy in Schnitzler syndrome | Allergy | 2012 | treatment | cohort | C | DOI |
| — | Krause K, et al. | Rilonacept in Schnitzler syndrome: an open-label study | — | 2012 | treatment | open label | B | PubMed |
| G10 | Gran JT, et al. | Anakinra case series and Schnitzler syndrome review | Scand J Rheumatol | 2011 | treatment | case series | C | DOI |
| B1 | Lipsker D | Schnitzler syndrome as paradigm of acquired autoinflammatory disease | Orphanet J Rare Dis | 2010 | pathophysiology | narrative review | B | DOI |
| G9 | Dybowski F, et al. | Anakinra success after failed rituximab: 12-month follow-up | Clin Exp Rheumatol | 2010 | treatment | case report | C | — |
| G7 | Schuster C, et al. | First observation of relapse under continuous anakinra therapy | Int J Dermatol | 2009 | treatment | case series | C | DOI |
| G4 | Dybowski F, et al. | Successful anakinra for refractory Schnitzler syndrome | Clin Exp Rheumatol | 2008 | treatment | case report | C | PubMed |
| A3 | de Koning HD, et al. | Landmark systematic review (94 patients) | Semin Arthritis Rheum | 2007 | epidemiology | systematic review | B | DOI |
| G3 | Eiling E, et al. | Rituximab failure vs anakinra success in same patient | J Am Acad Dermatol | 2007 | treatment | case report | C | DOI |
| I7 | Asli B, et al. | Pefloxacin treatment in Schnitzler syndrome | Arch Dermatol | 2007 | treatment | case series | C | DOI |
| D5 | Bertrand A, et al. | Three-year radiological follow-up of Schnitzler syndrome | Skeletal Radiol | 2006 | diagnostics | case report | C | DOI |
| G2 | de Koning HD, et al. | Anakinra efficacy in 3 patients; thalidomide comparison | Ann Rheum Dis | 2006 | treatment | case series | C | DOI |
| G1 | Martinez-Taboada VM, et al. | First successful anakinra treatment | Arthritis Rheum | 2005 | treatment | case report | C | DOI |
| I6 | Worm M, Kolde G | Thalidomide complete remission in Schnitzler syndrome | Br J Dermatol | 2003 | treatment | case series | C | DOI |
| A2 | Lipsker D, et al. | Lipsker diagnostic criteria for Schnitzler syndrome | Medicine | 2001 | diagnostics | case series | B | DOI |
| D4 | Lecouvet FE, et al. | MRI features of bone involvement in Schnitzler syndrome | AJR Am J Roentgenol | 2000 | diagnostics | case report | C | DOI |
| F1 | Verret JL, et al. | Original Schnitzler patient: fatal WM after 20 years | Ann Dermatol Venereol | 1993 | case reports | case report | C | PubMed |
Pathophysiology Narrative
Schnitzler syndrome is driven by dysregulated activation of the NLRP3 inflammasome, leading to excessive IL-1β production. This central role is proven by the dramatic, rapid response to anakinra (IL-1 receptor antagonist) — symptoms resolve within hours of the first injection.
The cascade begins with inflammasome assembly: NLRP3 recruits ASC and activates caspase-1, which cleaves pro-IL-1β into its active form. IL-1β then drives all the cardinal features — urticarial rash (via neutrophil recruitment to skin), recurrent fever, bone pain/osteosclerosis, arthralgia, and elevated CRP/ESR.
What triggers the inflammasome in the first place remains unresolved. Unlike CAPS (cryopyrin-associated periodic syndromes), where gain-of-function NLRP3 mutations are causative, no consistent genetic mutation has been found in Schnitzler syndrome. MYD88 L265P — the same somatic mutation found in >90% of Waldenström's macroglobulinemia — is present in ~30% of Schnitzler patients, suggesting a shared pathogenic link via NF-κB activation. But 70% of patients don't carry it.
The relationship between the obligate monoclonal IgM gammopathy and the autoinflammation is the central mystery. Three hypotheses compete: (1) a shared MYD88/NF-κB mechanism drives both, (2) the IgM paraprotein directly triggers inflammation, (3) they are independent consequences of an upstream event. The failure of rituximab (which depletes B cells and reduces IgM but doesn't control inflammation) argues against hypothesis 2.
Genetic Basis Narrative
The genetic basis of Schnitzler syndrome remains elusive. A landmark 32-gene sequencing study (Rowczenio et al. 2018) found no shared genetic alteration across patients, distinguishing it from monogenic autoinflammatory diseases like CAPS.
The most significant finding is MYD88 L265P, a somatic mutation present in ~30% of tested Schnitzler patients (Pathak et al. 2019). This same mutation occurs in >90% of Waldenström's macroglobulinemia cases, supporting a shared pathogenic mechanism via persistent NF-κB activation.
Somatic NLRP3 mosaicism has been identified in a small number of patients with the most severe phenotypes (de Koning et al. 2015), but this is rare and not a general explanation.
Emerging evidence (2024-2025) points to MEFV gene variants in some patients. MEFV encodes pyrin, an inflammasome inhibitor — variants could theoretically lower the threshold for inflammasome activation. The F2 gene (prothrombin) has also been implicated in one case. These findings suggest Schnitzler syndrome may involve multiple genetic modifiers rather than a single causative gene.